Shares of Evoke Pharma Inc. (NASDAQ:EVOK) were up 1.9% during mid-day trading on Wednesday . The stock traded as high as $2.12 and last traded at $2.11, with a volume of 208,695 shares trading hands. The stock had previously closed at $2.07.

Several analysts have issued reports on EVOK shares. FBR & Co upped their price objective on Evoke Pharma to $9.00 and gave the company an “outperform” rating in a research note on Tuesday, July 19th. Rodman & Renshaw lowered Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 price objective on the stock. in a research note on Monday, July 18th. Noble Financial restated a “hold” rating on shares of Evoke Pharma in a research note on Tuesday, August 16th. Brean Capital lowered Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, July 18th. Finally, Feltl & Co. lowered Evoke Pharma from a “strong-buy” rating to a “sell” rating in a research note on Monday, July 18th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. Evoke Pharma presently has a consensus rating of “Hold” and a consensus target price of $10.28.

The company’s market cap is $24.70 million. The stock has a 50 day moving average price of $3.96 and a 200 day moving average price of $4.66.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Monday, August 15th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.02. On average, analysts forecast that Evoke Pharma Inc. will post ($1.25) EPS for the current fiscal year.

In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of Evoke Pharma stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.